Limited paediatric data on COVID-19 suggest that it is less frequent and severe in children than in adults.[@R1] Spain is currently one of the most affected countries. Our aim was to describe the patients under the age of 18 years diagnosed with SARS-CoV-2 infection at Hospital La Paz (Madrid) in the first month of the outbreak (11 March to 9 April 2020). Inclusion criteria were all children who underwent PCR for SARS-CoV-2 in nasopharyngeal smears.

Out of 349 children, 58 (16.6%) had a positive PCR for SARS-CoV-2 ([table 1](#T1){ref-type="table"}). All had compatible symptoms, except two cases in which the PCR was indicated prior to intensive care unit (ICU) admission or surgery. Twenty-five (43%) children were followed up as outpatients. Nine of them (35%) attended a second time but none required hospital admission. Thirty-three (57%) children were admitted, after a median of 3 days of symptoms (IQR 2--5). Among inpatients, 14 (42.4%) received oxygen therapy for a median of 3 days (IQR 2--6.75), and 12 (36.4%) were given antibiotics (ceftriaxone 11/12). Three patients with severe disease received remdesivir, and tocilizumab was added in two with an inflammatory syndrome. Five children were admitted to the PICU (15% of those hospitalised), three for severe COVID-19, one for hypertensive crisis and the other for diabetic ketoacidosis. A 5-month-old infant with dilated cardiomyopathy and Hurler's disease died. Median hospital stay was 3 days (IQR 2--5).

###### 

Characteristics of 58 children with SARS-CoV-2 infection in Hospital La Paz, Madrid, Spain

  ----------------------------------------------------------------------------------------------------------------------
                                             All cases (n=58)    Outpatients (n=25)   Inpatients (n=33)     P value\*
  ------------------------------------------ ------------------- -------------------- --------------------- ------------
  Male sex                                   37 (63.8%)          15 (60%)             22 (66.7%)            0.801

  Median age in months (IQR)                 35.5 (3.3--146)     82 (6--151)          19.4 (1.4--117)       0.438

  Symptomatic household contact              30 (51.7%)          18 (72%)             12 (36.4%)            **0.0153**

  Underlying conditions                      23 (39.7%)          10 (40%)             13 (39.4%)            0.963

   Immunodeficiency (primary or secondary)   6 (26%)             3 (12%)              3 (9.1%)              

   Respiratory disease                       6 (26%)             1 (4%)               5 (15.2%)             

   Cardiovascular disease                    5 (21.7%)           1 (4%)               4 (12.1%)             

   Solid organ transplant                    2 (8.6%)            0                    2 (6.1%)              

   Nephropathy                               2 (8.6%)            0                    2 (6.1%)              

   Neurological disease                      1 (4.4%)            0                    1 (3%)                

   Vasculitis                                1 (4.4%)            0                    1 (3%)                

  Signs and symptoms                                                                                        

   Temperature \>37.9°C                      41 (70.7%)          18 (72%)             23 (69.7%)            0.849

   Cough                                     42 (72.4%)          18 (72%)             24 (72.7%)            0.951

   Rhinorrhoea                               33 (56.9%)          14 (56%)             19 (57.6%)            0.904

   Sore throat                               4 (6.9%)            2 (8%)               2 (6.1%)              0.773

   Breathing difficulty                      10 (17.2%)          2 (8%)               8 (24.2%)             0.105

   Vomiting                                  9 (15.5%)           3 (12%)              6 (18.2%)             0.520

   Diarrhoea                                 7 (12.1%)           5 (20%)              2 (6.1%)              0.107

   Headache                                  8 (13.8%)           4 (16%)              4 (12.1%)             0.671

   Myalgia                                   2 (3.4%)            2 (8%)               0                     0.098

   Rash                                      2 (3.4%)            0                    2 (6.1%)              0.693

   Loss of taste                             1 (1.7%)            1 (4%)               0                     0.246

   Anosmia                                   1 (1.7%)            1 (4%)               0                     0.246

   SatO~2~ \<93%                             14 (24.1%)          0                    14 (42.4%)            **0.002**

  Chest radiograph                           40 (69%)            15 (60%)             25 (75.8%)            0.318

   Normal                                    5 (12.5%)           2 (13.3%)            3 (12%)               0.671

   Perihilar infiltrates                     15 (37.5%)          6 (40%)              9 (36%)               

   Ground glass interstitial pattern         10 (25%)            5 (33.3%)            5 (20%)               

   Lobar consolidation                       3 (7.5%)            1 (6.7%)             2 (8%)                

   Multilobar consolidation                  7 (17.5%)           1 (6.7%)             6 (24%)               

   Blood tests†                              43 (74.1%)          14 (56%)             29 (87.9%)            **0.0137**

   Leucocytes/mm^3^ (median (IQR))           9145 (5830--9145)   8010 (5562--\        9145 (5935--12 107)   0.498
                                                                 10 745)                                    

   Lymphocytes/mm^3^ (median (IQR))          2390 (970--3930)    2700 (2100--5110)    1945 (835--4140)      0.192

   D-dimer; mg/dL (IQR)                      903 (717--2143)     403 (260--867)       920 (710--2112)       0.912

   Procalcitonin; ng/mL (IQR)                0.11 (0.06--0.16)   0.08 (0.03--0.17)    0.13 (0.09--0.16)     0.338

   C reactive protein; mg/L (IQR)            7.4 (0.67--26.3)    7.4 (0.6--31)        7.5 (0.6--23)         0.853

  Diagnosis                                                                                                 

   Febrile syndrome                          12 (20.7%)          3 (12%)              9 (27.3%)             **0.038**

   Upper respiratory tract infection         22 (37.9%)          16 (64%)             6 (18.2%)             

   Pneumonia                                 18 (31%)            5 (20%)              13 (39.4%)            

   Other‡                                    6 (10.3%)           1 (4%)               5 (15.1%)             

  Treatment                                                                                                 

   Hydroxychloroquine                        31 (53.4%)          11 (44%)             20 (60.6%)            0.322

   Lopinavir/ritonavir                       2                   0                    2 (6%)                --

   Tocilizumab                               2                   0                    2 (6%)                --

   Remdesivir                                3                   0                    3 (9%)                --
  ----------------------------------------------------------------------------------------------------------------------

\*Comparison between outpatients and inpatients.

†In patients with more than one blood test result, values represent highest leucocytes, D-dimer, procalcitonin and C reactive protein and lowest lymphocytes.

‡Diabetic ketoacidosis, hypertensive emergency, appendicitis, 2 cases of febrile urinary tract infection (*Escherichia coli* and *Enterococcus faecalis*), recurrent wheezing.

This is the largest series of children with COVID-19 in Spain to date. Most children had good outcomes, including five outpatients with pneumonia. On the other hand, the rates of hospital (57%) and ICU (15%) admission were high. These data must be interpreted carefully. In China, where hospitalisation of only 2%--3% of infected children has been described,[@R2] numerous asymptomatic or mildly symptomatic children, in the context of infections at home, were tested.[@R3] In Spain, during the study period diagnostic tests were only conducted in those children with compatible respiratory symptoms and criteria for hospitalisation or underlying chronic pathology.[@R4] Children with mild symptoms were not tested even if there was a confirmed case in the household. About 40% of children in our series had underlying medical conditions. These patients consulted promptly after symptom onset, and according to national recommendations, underwent viral testing even with mild symptoms. In our series, their outcome was similar to healthy children. Although the role of hydroxychloroquine in the treatment of COVID-19 remains to be clarified, we used it in a high percentage of patients following local recommendations,[@R5] without side effects.

Our study has several limitations, including its retrospective design. It is the experience of a single tertiary centre, and screening was carried out only in cases that required hospitalisation or had chronic diseases. Despite this, we consider it to be a reliable description of COVID-19 in children in Spain.
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